AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01040286
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.0 mg
Trial: NCT00002499
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01885260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Trial: NCT00003495
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01447849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills twice a day for one week.
Trial: NCT00002502
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02778399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for oral administration once daily
Trial: NCT02778399
Drug: OBE2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE2109 tablets for oral administration once daily
Trial: NCT00004202
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01263106
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-mg LY2216684 oral dose
Trial: NCT01263106
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-mg theophylline oral dose
Trial: NCT01364974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00101998
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04306146
Drug: CAD-9303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
Trial: NCT04306146
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT02714608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
Trial: NCT00543868
Drug: MK0782
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03855176
Drug: Vaqta Injectable Product
RxNorm normalized name: Vaqta Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vaccine against hepatitis A virus
Trial: NCT02611830
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab subcutaneous injection placebo
Trial: NCT02215733
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: other than telmisartan
Trial: NCT02215733
Drug: ACEI
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215733
Drug: Beta-blockers
RxNorm normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215733
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04360785
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
Trial: NCT01246180
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
Trial: NCT01246180
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
Trial: NCT00568698
Drug: Placebo to match hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02895360
Drug: BAL101553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
Trial: NCT02412449
Drug: AKB-6548 tablet, reference formulation given in the fasted state
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02412449
Drug: AKB-6548 tablet, test formulation given in the fasted state.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02412449
Drug: AKB-6548 tablet, test formulation given in the fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00583271
Drug: 98% dehydrated alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
Trial: NCT04072705
Drug: General principles of care and judgement of researcher
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
Trial: NCT03712449
Drug: BOTOX Cosmetic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
Trial: NCT00415701
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
Trial: NCT00415701
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
Trial: NCT04109742
Drug: phosphatidylcholine-curcumin complex supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a dietary curcumin supplement given at two different doses
Trial: NCT02918929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match EDP 305
Trial: NCT00479089
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg by mouth daily, without break.
Trial: NCT03158389
Drug: APG101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly i.v.
Trial: NCT02165397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo capsules orally.
Trial: NCT03297398
Drug: Group-1 (15mg, OPK-88004)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, OPK-88004
Trial: NCT03297398
Drug: Group-2 (25 mg,OPK-88004)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg,OPK-88004
Trial: NCT03430050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
Trial: NCT03016598
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Trial: NCT01113671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: includes inactive Ingredients
Trial: NCT03757078
Drug: Relief Pro rectal suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
Trial: NCT03548493
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
Trial: NCT01648595
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
Trial: NCT01963715
Drug: IMGN289
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00900783
Drug: FV-100 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, for seven days
Trial: NCT04424875
Drug: 3 mg melatonin
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
Trial: NCT04424875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
Trial: NCT00965120
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic infusion of placebo (saline).
Trial: NCT02143141
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Trial: NCT02780505
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement.
Trial: NCT00561899
Drug: intermittent preventive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Trial: NCT00005946
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00451828
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/day
Trial: NCT02602483
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02602483
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00458393
Drug: daily TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral medication
Trial: NCT00458393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral medication
Trial: NCT00226122
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin capsules 50 mg
Trial: NCT00832000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a day; in pill form
Trial: NCT04718233
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered orally in patients with recurrent pregnancy loss
Trial: NCT03562429
Drug: TGFP
RxNorm normalized name: Transforming Growth Factor-Beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Trial: NCT00507221
Drug: Current standard of care in Kenya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of care for HIV patients in Kenya based on WHO guidelines.
Trial: NCT02342145
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
Trial: NCT01233609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage per subject weight- same schedule as the active comparator
Trial: NCT01046422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 0mg, Daily, 28 days
Trial: NCT04197479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablets
Trial: NCT01101061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT02033473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clamp reference during which a placebo solution (saline solution) will be administered
Trial: NCT03819270
Drug: LY3372689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03819270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00263575
Drug: EN3267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
Trial: NCT04340856
Drug: Laxatives
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
Trial: NCT01114308
Drug: placebo implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant contains ethylene vinyl acetate
Trial: NCT01639794
Drug: Vesitirim™ (Solifenacin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05809336
Drug: Inosine 0.2g orally 3 times/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
Trial: NCT05809336
Drug: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor ± chemotherapy/targeting
Trial: NCT00296387
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00641173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with placebo
Trial: NCT01728623
Drug: E7080 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7080 is administered as continuous once daily dosing in an uncontrolled manner
Trial: NCT02787447
Drug: TKI
RxNorm normalized name: Catkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Trial: NCT02787447
Drug: Thymosin Alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
Trial: NCT00532246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928680
Drug: Cisplatin/Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
Trial: NCT01580683
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
Trial: NCT04138342
Drug: Topical approved placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
Trial: NCT00020722
Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2.
Trial: NCT03363659
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram is taken orally, twice daily.
Trial: NCT04543812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Trial: NCT01130168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment
Trial: NCT01130168
Drug: Comparator: ISMN ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
Trial: NCT02087215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03990636
Drug: Metil 5-aminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
Trial: NCT00177021
Drug: Aldara Cream 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03075956
Drug: 5 mg E4 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
Trial: NCT03075956
Drug: 15 mg E4 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
Trial: NCT03075956
Drug: 45 mg E4 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
Trial: NCT01283022
Drug: MVI 200
RxNorm normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Trial: NCT03075956
Drug: 15 mg E4 multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
Trial: NCT02635386
Drug: EQW plus DAPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
Trial: NCT01216293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching capsules
Trial: NCT04302129
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
Trial: NCT01159522
Drug: SCB01A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
Trial: NCT04592081
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextenza 0.4Mg Ophthalmic Insert